Candidate early predictive plasma protein markers of doxorubicin-induced chronic cardiotoxicity in B6C3F(1) mice
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Desai, Varsha G. | - |
dc.contributor.author | Lee, Taewon | - |
dc.contributor.author | Moland, Carrie L. | - |
dc.contributor.author | Vijay, Vikrant | - |
dc.contributor.author | Han, Tao | - |
dc.contributor.author | Lewis, Sherry M. | - |
dc.contributor.author | Herman, Eugene H. | - |
dc.contributor.author | Fuscoe, James C. | - |
dc.date.accessioned | 2021-09-01T21:30:19Z | - |
dc.date.available | 2021-09-01T21:30:19Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-01-15 | - |
dc.identifier.issn | 0041-008X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/68289 | - |
dc.description.abstract | Cardiotoxicity is a serious adverse effect of doxorubicin (DOX) treatment in cancer patients. Currently, there is a lack of sensitive biomarkers to predict the risk of DOX-induced cardiotoxicity. Using SOMAmer-based proteomic technology, 1129 proteins were profiled to identify potential early biomarkers of cardiotoxicity in plasma from male B6C3F(1) mice given a weekly intravenous dose of 3 mg/kg DOX or saline (SAL) for 2, 3, 4, 6, or 8 weeks (6, 9, 12, 18, or 24 mg/kg cumulative DOX doses, respectively). Also, a group of mice received the cardio-protectant, dexrazoxane (DXZ; 60 mg/kg; intraperitoneal) 30 min before a weekly DOX or SAL dose. Proteomic analysis in plasma collected a week after the last dose showed a significant >= 1.2-fold change in level of 18 proteins in DOX-treated mice compared to SAL-treated counterparts during 8-week exposure. Of these, neurogenic locus notch homolog protein 1 (NOTCH1), von Willebrand factor (vWF), mitochondria) glutamate carrier 2, Wnt inhibitory factor 1, legumain, and mannan-binding lectin serine protease 1 were increased in plasma at 6 mg/kg cumulative DOX dose, prior to the release of myocardial injury marker, cardiac troponin I at 12 mg/kg and higher cumulative doses. These six proteins also remained significantly elevated following myocardial injury or pathology at 24 mg/kg. Pretreatment of mice with DXZ significantly attenuated DOX-induced elevated levels of only NOTCH1 and vWF with mitigation of cardiotoxicity. This suggests NOTCH1 and vWF as candidate early biomarkers of DOX cardiotoxicity, which may help in addressing a clinically important question of identifying cancer patients at risk for cardiotoxicity. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ACADEMIC PRESS INC ELSEVIER SCIENCE | - |
dc.subject | VON-WILLEBRAND-FACTOR | - |
dc.subject | MYOCARDIAL-INFARCTION | - |
dc.subject | NT-PROBNP | - |
dc.subject | MULTIPLE BIOMARKERS | - |
dc.subject | NOTCH PATHWAY | - |
dc.subject | HEART | - |
dc.subject | CARDIOMYOCYTES | - |
dc.subject | ACTIVATION | - |
dc.subject | IDENTIFICATION | - |
dc.subject | DEXRAZOXANE | - |
dc.title | Candidate early predictive plasma protein markers of doxorubicin-induced chronic cardiotoxicity in B6C3F(1) mice | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Taewon | - |
dc.identifier.doi | 10.1016/j.taap.2018.11.016 | - |
dc.identifier.scopusid | 2-s2.0-85058372053 | - |
dc.identifier.wosid | 000457068000017 | - |
dc.identifier.bibliographicCitation | TOXICOLOGY AND APPLIED PHARMACOLOGY, v.363, pp.164 - 173 | - |
dc.relation.isPartOf | TOXICOLOGY AND APPLIED PHARMACOLOGY | - |
dc.citation.title | TOXICOLOGY AND APPLIED PHARMACOLOGY | - |
dc.citation.volume | 363 | - |
dc.citation.startPage | 164 | - |
dc.citation.endPage | 173 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Toxicology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Toxicology | - |
dc.subject.keywordPlus | VON-WILLEBRAND-FACTOR | - |
dc.subject.keywordPlus | MYOCARDIAL-INFARCTION | - |
dc.subject.keywordPlus | NT-PROBNP | - |
dc.subject.keywordPlus | MULTIPLE BIOMARKERS | - |
dc.subject.keywordPlus | NOTCH PATHWAY | - |
dc.subject.keywordPlus | HEART | - |
dc.subject.keywordPlus | CARDIOMYOCYTES | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | DEXRAZOXANE | - |
dc.subject.keywordAuthor | Cardiotoxicity | - |
dc.subject.keywordAuthor | Doxorubicin | - |
dc.subject.keywordAuthor | Dexrazoxane | - |
dc.subject.keywordAuthor | Mouse Plasma | - |
dc.subject.keywordAuthor | Biomarkers | - |
dc.subject.keywordAuthor | SOMAscan (TM) Proteomic Assay | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.